International Stem Cell Corporation's Human Parthenogenetic Stem Cells to be used in the Development of Treatments for Liver Disease
Willenbring Lab - May 14, 2008
"International Stem Cell Corporation announced today that its human parthenogenetic stem cell lines will be used in studies aimed at creating liver cells to treat human liver disease. ......Holger Willenbring, MD, UCSF assistant professor of surgery, will direct the research. "The fact that Dr. Willenbring and the University of California at San Francisco are testing the ability of ISCO's human parthenogenetic stem cells to form liver cells is a strong validation of their potential value in creating therapeutic cells that have significant immune rejection advantages and significant ethical advantages," said Jeffrey Janus, ISCO's President."
Tags: Embryonic Stem Cells